---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-21-016848"
form_type: "8-K"
ticker: "LMAT"
cik: "0001158895"
company_name: "LEMAITRE VASCULAR INC"
filed_at: "2021-07-13T23:59:59+00:00"
generated_at: "2026-06-30T05:37:47.441097+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# LeMaitre Q2 net sales $40.7M (+64%), op income up ~128%; launches stock offering, receives CE marks

## Summary
- Q2 preliminary net sales $40.7M (+64% reported, +35% organic vs Q2 2020).
- Operating income ~$10.9-11.3M, up ~128% at midpoint vs Q2 2020.
- Gross margin 65.5-66.1%, down 2.7pp at midpoint due to inventory write-downs and manufacturing inefficiencies.
- Commenced underwritten public offering of common stock; proceeds to repay $23M debt and for general corporate purposes.
- Received renewed CE marks for five vascular products expiring 2024; XenoSure indications narrowed (no neuro/cardiac).

## SEC filing metadata
- accession: 0001437749-21-016848
- form_type: 8-K
- ticker: LMAT
- cik: 0001158895
- company_name: LEMAITRE VASCULAR INC
- filed_at: 2021-07-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1158895/000143774921016848/0001437749-21-016848-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1158895/000143774921016848/lmat20210712_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-21-016848
- JSON: https://secwatch.observer/filing/0001437749-21-016848.json
- Plain text: https://secwatch.observer/filing/0001437749-21-016848.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.